PENETRATION OF 5-FLUOROURACIL AND PRODRUGS ACROSS THE INTESTINE OF THE ALBINO RABBIT - EVIDENCE FOR SHIFT IN ABSORPTION SITE FROM THE UPPER TO THE LOWER REGION OF THE GASTROINTESTINAL-TRACT BY PRODRUGS

被引:9
作者
BUUR, A [1 ]
YAMAMOTO, A [1 ]
LEE, VHL [1 ]
机构
[1] UNIV SO CALIF,SCH PHARM,1985 ZONA AVE,LOS ANGELES,CA 90033
关键词
5; fluorouracil; carrier-mediated transport; prodrugs; rectal absorption; site targeted delivery;
D O I
10.1016/0168-3659(90)90059-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The penetration of 5-fluorouracil (5-FU) and five of its prodrugs across the duodenum, jejunum, ileum, colon and rectum of the albino rabbit was studied using the modified Ussing chamber. The prodrugs were the 1-ethoxycarbonyl, 1-isopropyloxycarbonyl, 1-butyloxycarbonyl, 1-cyclohexyloxycarbonyl and 1-butyryloxymethyl derivatives of 5-FU. Appearance of 5-FU and its prodrugs on the serosal side was monitored by reversed phase HPLC. 5-FU penetrated the jejunum most readily, followed by the duodenum, ileum, rectum and colon in that order. This rank order of penetration was essentially reversed by all five prodrugs. In particular, all five prodrugs reduced the penetration of 5-FU across duodenal, jejunal and ileal segments by a factor of 3-100, while enhancing its penetration across colonic and rectal segments by a factor of 5-12. The net result was a shift in the principal absorption site of 5-FU from the upper to the lower region of gastrointestinal tract. The prodrugs were as effective as the penetration enhancers sodium glycocholate and EDTA in enhancing the rectal penetration of 5-FU, but perhaps without the liability of local irritation and toxicity associated with most penetration enhancers. The reduction in 5-FU transport across the small intestinal segments by prodrugs may be due to a shift in the pathway of drug penetration from para- to trans-cellular rather than to reduced affinity of the prodrugs for the 5-FU carrier. This possibility remains to be investigated. © 1990.
引用
收藏
页码:43 / 51
页数:9
相关论文
共 43 条
[1]  
DeVita, Hellman, Rosenberg, Cancer, Principles and Practice of Oncology, (1985)
[2]  
Diasio, Harris, Clinical pharmacology of 5-fluorouracil, Clin. Pharmacokin., 16, pp. 215-237, (1989)
[3]  
Christophidis, Vajda, Lucas, Drummer, Moon, Louis, Fluorouracil therapy in patients a pharmacokinetic comparison of various rates and routes of administration, Clinical Pharmacokinetics, 3, pp. 330-336, (1978)
[4]  
Buur, Bundgaard, Prodrugs of 5-fluorouracil. I. Hydrolysis kinetics and physicochemical properties of various N-acyl derivatives of 5-fluorouracil, Int. J. Pharm., 21, pp. 349-364, (1984)
[5]  
Buur, Bundgaard, Prodrugs of 5-fluorouracil. II. Hydrolysis kinetics, bioactivation, solubility and lipophilicity of N-alkoxycarbonyl derivatives of 5-fluorouracil, Arch. Pharm. Chemi., Sci. Ed., 12, pp. 37-44, (1984)
[6]  
Buur, Bundgaard, Prodrugs of 5-fluorouracil. III. Hydrolysis kinetics in aqueous solution and biological media, lipophilicity and solubility of various 1-carbamoyl derivatives of 5-fluorouracil, Int. J. Pharm., 23, pp. 209-222, (1985)
[7]  
Buur, Bundgaard, Falch, Prodrugs of 5-fluorouracil. IV. Hydrolysis kinetics, bioactivation and physicochemical properties of various N-acyloxymethyl derivatives of 5-fluorouracil, Int. J. Pharm., 24, pp. 43-60, (1985)
[8]  
Buur, Bundgaard, Prodrugs of 5-fluorouracil. V. 1-Alkoxycarbonyl derivatives as potential prodrug forms for improved rectal or oral delivery of 5-fluoroacil, J. Pharm. Sci., 75, pp. 522-527, (1986)
[9]  
Buur, Bundgaard, Prodrugs of 5-fluorouracil. VI. Hydrolysis kinetics and bioactivation of 3-nicotinoyl-5-fluorouracil and various 1-substituted derivatives of 3-benzoyl-5-fluorouracil, Arch. Pharm. Chemi, Sci. Ed., 14, pp. 99-112, (1986)
[10]  
Buur, Bundgaard, Falch, Prodrugs of 5-fluorouracil. VII. Hydrolysis kinetics and physicochemical properties of N-ethoxy- and N-phenoxycarbonyloxymethyl derivatives of 5-fluorouracil, Acta Pharm. Suec., 23, pp. 205-216, (1986)